de Heus RAA, et al. - In order to determine the prevalence of orthostatic hypotension (OH) in relation to antihypertensive treatment in patients with Alzheimer disease, researchers performed a secondary analysis of a randomized controlled trial in which they randomized 477 patients with mild-to-moderate Alzheimer disease to receive either nilvadipine (calcium-channel blocker) 8 mg/day or placebo for 78 weeks. At 7 follow-up visits, they looked for the presence of OH (blood pressure drop ≥ 20/≥ 10 mmHg following 1 minute of standing) and OH-associated adverse events (dizziness, syncope, falls, and fractures). No significantly increased risk of OH was found in relation to initiation of a low dose of antihypertensive treatment in patients with mild-to-moderate Alzheimer disease.